SCH 900271
| SCH 900271 | |
|---|---|
 |
|
|
5-(3-(1-Methylcyclopropyl)propyl)-1H-pyrano[2,3-d]pyrimidine-2,4,7(3H)-trione |
|
| Identifiers | |
| Jmol-3D images | Image 1 |
|
|
| Properties | |
| Molecular formula | C14H16N2O4 |
| Molar mass | 276.29 g mol−1 |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
| Infobox references | |
SCH 900271 is a nicotinic acid derivative designed to treat dyslipidemia. It reduced plasma free fatty acids levels, but without significant flushing, a side effect common with niacin that limits its usefulness. SCH 900271 is currently in human trials.[1]
References
- ^ Palani, Anandan (November 2011). "Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia". ACS Medicinal Chemistry Letters. doi:10.1021/ml200243g.
